D. Tang

发表

Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study

G. Deshpande, N. Shah, T. Gu, 2016, Drugs - Real World Outcomes.

Systematic review and network meta-analysis of the ef fi cacy and safety of tumour necrosis factor inhibitor – methotrexate combination therapy versus triple therapy in rheumatoid arthritis

D. Collier, J. Pope, R. Fleischmann, 2017 .

Effectiveness and costs of biologics in veterans with rheumatoid arthritis

J. Curtis, D. Harrison, B. Sauer, 2015 .

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis

T. Mikuls, J. Curtis, D. Harrison, 2017, Arthritis care & research.

Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor–methotrexate combination therapy versus triple therapy in rheumatoid arthritis

D. Collier, J. Pope, R. V. van Vollenhoven, 2017, RMD Open.

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study

D. Harrison, G. Deshpande, N. Shah, 2015 .

Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.

M. Bonafede, D. Harrison, B. Stolshek, 2018, The American journal of managed care.

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis

J. Walsh, D. Harrison, B. Sauer, 2016, Journal of medical economics.

Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis

D. Collier, M. Bonafede, D. Harrison, 2015, Arthritis care & research.

A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients

B. Chastek, B. Stolshek, Damon Van Voorhis, 2016, Advances in Therapy.